Takeda Pharmaceutical Co. Ltd. TAK

What this company does

Takeda is a global R&D-driven biopharmaceutical company focused on discovering and delivering treatments in the therapeutic areas of gastrointestinal and inflammation, neuroscience and oncology, as well as through its plasma-derived therapies and vaccines business. Its prescription drugs are marketed worldwide, and it has approximately 47,000 employees. Commercial efforts are focused on six business areas — GI, Rare Diseases, PDT, Oncology, Vaccines and Neuroscience — which in the fiscal year ended March 31, 2026 accounted for 95.0% of total revenue. In GI, principal products include ENTYVIO, a treatment for moderate to severe ulcerative colitis and Crohn's disease. In Rare Diseases, they include TAKHZYRO, a fully human monoclonal antibody for the prevention of hereditary angioedema attacks. In Plasma-Derived Therapies, products include GAMMAGARD LIQUID/KIOVIG, a liquid formulation of the antibody replacement therapy immunoglobulin, for the treatment of patients with primary immunodeficiencies and of adult patients with multifocal motor neuropathy. In Oncology, offerings include ADCETRIS, an anti-cancer agent used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. In Neuroscience, principal products include VYVANSE/ELVANSE, a stimulant medication indicated for the treatment of attention deficit hyperactivity disorder and of moderate to severe binge eating disorder in adults.

Written from the business description in TAKEDA PHARMACEUTICAL CO LTD's annual report to the U.S. Securities and Exchange Commission, filed 17 June 2026. Every sentence was checked against that document before publication.